News Headlines Article

Cancer-Drug Shortages Targeted by Stopgap U.S. Approvals
San Francisco Chronicle

Cancer-drug shortages that have plagued U.S. hospitals are being targeted by Food and Drug Administration decisions, announced today, giving generic-drug makers clearance to provide stopgap replacements. Use of the drugs Doxil, for treating ovarian cancer and multiple myeloma, and methotrexate, for leukemia and tumors of the breast and lung, will be bolstered by the decisions, the agency said. The cancer drugs are among 220 types of medications deemed to be in short supply in the U.S. by the American Society of Health-System Pharmacists.